Quantcast

Industry news that matters to you.  Learn more

New Biomarker Allows Better Prediction of Survival for Patients with Colorectal Metastases

Liver metastases are formed from cancer cells that have originated in other organs and migrated to the liver via the bloodstream. Colorectal cancer (cancer of the colon/rectum) can be successfully treated by surgical resection of the metastases in combination with chemotherapy. In collaboration with the University of Southern California (USA), a MedUni Vienna research team has now identified a new biomarker that allows better prediction of survival following surgical removal of the metastases, as well as a change in the clinical significance of the biomarker following chemotherapy.

St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit

Genomic Health (Nasdaq: GHDX) recently announced that the 14th St. Gallen International Breast Cancer Conference Expert Panel, for the third time, recognized the Oncotype DX® breast cancer test for its ability to provide not only prognostic but also predictive information regarding the likelihood of chemotherapy benefit for patients with early-stage, estrogen receptor-positive, invasive breast cancer. Oncotype DX was the only multi-gene test accepted with a strong majority of panellists supporting it as a predictive tool to guide chemotherapy treatment decision making. The new guidelines were recently published online in the Advance Access section of Annals of Oncology and will appear in a future print issue.

WaveCheck receives $100,000 in Funding

People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).

Almac Publishes Breast Cancer Chemotherapy Response Assay in the Journal of the National Cancer Institute

Almac’s Diagnostics business unit recently announced the publication of its breast cancer chemotherapy response assay in the Journal of the National Cancer Institute (JNCI).

Novogen Launches Joint Venture Aimed at Developing Drugs to Fight Ovarian Cancer

Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, recently announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.